石杉碱甲联合丁苯酞治疗脑梗死后轻度认知障碍的临床疗效及对血清Hcy、hs-CRP的影响  

Clinical efficacy of huperzine A combined with butylphthalide in treating mild cognitive impairment induced by cerebral infarction and its effect on serum Hcy and hs-CRP

作　　者：钱铭净[1] 张东伟[1] QIAN Ming-jing;ZHANG Dong-wei(Department of Neurology,The First People’s Hospital of Huzhou,Huzhou 313000,China)

机构地区：[1]湖州市第一人民医院神经内科,浙江湖州313000

出　　处：《健康研究》2019年第2期201-204,共4页Health Research

摘　　要：目的探讨石杉碱甲联合丁苯酞治疗脑梗死后轻度认知障碍的临床效果。方法 120例脑梗死后轻度认知障碍患者分为对照组和观察组各60例,对照组在常规治疗的基础上口服石杉碱甲片,观察组在对照组基础上静脉滴注丁苯酞氯化钠注射液,2周为1个疗程;连续治疗2个疗程后,比较两组患者治疗前后NIHSS评分、MoCA评分、Barthel指数、血清中Hcy、hs-CRP水平,比较两组患者的临床疗效及不良反应发生情况。结果治疗后,两组的NIHSS评分、MoCA评分、Barthel指数及血清Hcy、hs-CRP均较治疗前显著改善,且观察组较对照组改善更明显,差异有统计学意义(P<0.05)。观察组治疗后的总有效率(91.7%)显著高于对照组(81.7%),差异有统计学意义(χ~2=4.421,P<0.05);两组不良反应发生率差异无统计学意义(χ~2=0.072,P>0.05)。结论石杉碱甲联合丁苯酞治疗脑梗死后轻度认知障碍具有较好的临床疗效,且用药安全性高。Objective To evaluate the clinical efficacy of huperzine A combined with butylphthalide in the treatment of mild cognitive impairment induced by cerebral infarction. Methods Firstly, 120 patients with mild cognitive impairment resulting from cerebral infarction were divided into a control group ( n =60) and an experimental group ( n =60). Next, the control group were treated with huperzine A tablets in addition to conventional treatment while the exprimental group were administered with intravenous infusion of sodium butylphthalide in addition to medication as given to the control. Both groups were subjected to two courses of medication, each lasting 2 weeks. After two courses of medication, the NIHSS score, MoCA score, Barthel index, serum Hcy and hs-CRP levels of the two groups as observed before and after treatment as well as the clinical efficacy and adverse reactions of the two groups were compared. Results The NIHSS score, MoCA score, Barthel index, serum Hcy and hs-CRP in the two groups as observed after treatment significantly bettered, with those of the experimental group being better than those of the control. The differences were statistically significant ( P <0.05). The total effective rate (91.7%) in the experimental group was significantly higher than that in the control group (81.7%). The difference was statistically significant (χ 2 =4.421, P <0.05). No significant difference was found between the two groups in the incidence of adverse reactions (χ 2 =0.072, P >0.05). Conclusions Huperzine A combined with butylphthalide as a medication for the treatment of mild cognitive impairment after cerebral infarction can result in good clinical efficacy and high safety.

关 键 词：石杉碱甲 丁苯酞 脑梗死 轻度认知障碍 

分 类 号：R459.9[医药卫生—治疗学]